Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide

Overview

Journal Diabetes Ther

Specialty Cardiology & Vascular Diseases

Date 2022 Aug 13

PMID 35963931

Authors

Yunyi Le

Kun Yang

Jin Yang

Wei Fu

Wenhua Xiao

Rui Wei

Tianpei Hong

Affiliations

Soon will be listed here.

Abstract

Introduction: We aimed to investigate whether treatment with exenatide could increase time in range (TIR) and decrease glycemic variability, and to evaluate the association between TIR and endothelial injury in patients with type 2 diabetes mellitus (T2DM).

Methods: Two-hundred patients with T2DM treated with exenatide for 16 weeks were included in this study. Seven-point fingerstick blood glucose was used to evaluate derived TIR and glycemic variability. The serum levels of soluble endothelial cell protein C receptor (sEPCR) and von Willebrand factor (vWF) were measured. Ninety-three patients having the data of endothelial injury markers were categorized as derived TIR > 70% or ≤ 70% after the treatment and the association between TIR and endothelial injury were evaluated.

Results: Treatment with exenatide for 16 weeks resulted in a significant reduction in fasting blood glucose, postprandial 2 h blood glucose, and glycated hemoglobin A1c (HbA1c) levels in patients with T2DM. Compared with baseline, derived TIR value was significantly increased [85.7 (57.1, 100.0) % vs. 42.9 (14.9, 71.4) %, P < 0.001], and the parameters of glycemic variability were remarkably decreased after the treatment. After the treatment, serum sEPCR level was significantly decreased from baseline in patients with TIR > 70% [74.5 (32.8, 122.5) ng/mL vs. 96.9 (48.5, 150.9) ng/mL, P = 0.006] but not in those with TIR ≤ 70%; serum vWF level was remarkably decreased in patients with TIR > 70% [from 1166.2 (848.1, 1335.5) mIU/mL to 907.4 (674.3, 1335.1) mIU/mL, P = 0.001] while this effect was modest in those with TIR ≤ 70%.

Conclusions: Treatment with exenatide increases TIR and decreases glycemic variability in patients with T2DM. Moreover, the amelioration of endothelial injury is more pronounced in patients with TIR > 70% after the treatment.

Trial Registration: ChiCTR-IPR-15006558 (registered, 27 May 2015).

Citing Articles

Association between glycemia risk index and arterial stiffness in type 2 diabetes.

Cai L, Shen W, Li J, Wang B, Sun Y, Chen Y J Diabetes Investig. 2024; 15(5):614-622.

PMID: 38251792 PMC: 11060162. DOI: 10.1111/jdi.14153.

References

Ogurtsova K, Guariguata L, Barengo N, Ruiz P, Sacre J, Karuranga S . IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021. Diabetes Res Clin Pract. 2021; 183:109118. DOI: 10.1016/j.diabres.2021.109118. View

Holman R, Paul S, Bethel M, Matthews D, Neil H . 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15):1577-89. DOI: 10.1056/NEJMoa0806470. View

Vigersky R . Going beyond HbA1c to understand the benefits of advanced diabetes therapies. J Diabetes. 2018; 11(1):23-31. DOI: 10.1111/1753-0407.12846. View

Ceriello A, Monnier L, Owens D . Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol. 2018; 7(3):221-230. DOI: 10.1016/S2213-8587(18)30136-0. View

Battelino T, Danne T, Bergenstal R, Amiel S, Beck R, Biester T . Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019; 42(8):1593-1603. PMC: 6973648. DOI: 10.2337/dci19-0028. View

Beck R, Bergenstal R, Riddlesworth T, Kollman C, Li Z, Brown A . Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2018; 42(3):400-405. PMC: 6905478. DOI: 10.2337/dc18-1444. View

Lu J, Ma X, Shen Y, Wu Q, Wang R, Zhang L . Time in Range Is Associated with Carotid Intima-Media Thickness in Type 2 Diabetes. Diabetes Technol Ther. 2019; 22(2):72-78. DOI: 10.1089/dia.2019.0251. View

Cho N, Shaw J, Karuranga S, Huang Y, da Rocha Fernandes J, Ohlrogge A . IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018; 138:271-281. DOI: 10.1016/j.diabres.2018.02.023. View

Santilli F, DArdes D, Davi G . Oxidative stress in chronic vascular disease: From prediction to prevention. Vascul Pharmacol. 2015; 74:23-37. DOI: 10.1016/j.vph.2015.09.003. View

10.

Campbell J, Drucker D . Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013; 17(6):819-837. DOI: 10.1016/j.cmet.2013.04.008. View

11.

Lim S, Oh T, Dawson J, Sattar N . Diabetes drugs and stroke risk: Intensive versus conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials. Diabetes Obes Metab. 2019; 22(1):6-15. DOI: 10.1111/dom.13850. View

12.

Avgerinos I, Karagiannis T, Malandris K, Liakos A, Mainou M, Bekiari E . Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2018; 21(1):188-193. DOI: 10.1111/dom.13484. View

13.

Yang J, Xiao W, Guo L, Li Q, Zhong L, Yang J . Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial. Acta Diabetol. 2020; 57(8):991-1000. DOI: 10.1007/s00592-020-01510-y. View

14.

Tang X, Li S, Wang Y, Wang M, Yin Q, Mu P . Glycemic variability evaluated by continuous glucose monitoring system is associated with the 10-y cardiovascular risk of diabetic patients with well-controlled HbA1c. Clin Chim Acta. 2016; 461:146-50. DOI: 10.1016/j.cca.2016.08.004. View

15.

Bonora E, Calcaterra F, Lombardi S, BONFANTE N, Formentini G, Bonadonna R . Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care. 2001; 24(12):2023-9. DOI: 10.2337/diacare.24.12.2023. View

16.

DeFronzo R, Ratner R, Han J, Kim D, Fineman M, Baron A . Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28(5):1092-100. DOI: 10.2337/diacare.28.5.1092. View

17.

Fehse F, Trautmann M, Holst J, Halseth A, Nanayakkara N, Nielsen L . Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90(11):5991-7. DOI: 10.1210/jc.2005-1093. View

18.

Saboo B, Erande S, Unnikrishnan A . A prospective multicentre open label study to assess effect of Teneligliptin on glycemic control through parameters of time in range (TIR) Metric using continuous glucose monitoring (TOP-TIR study). Diabetes Metab Syndr. 2022; 16(2):102394. DOI: 10.1016/j.dsx.2022.102394. View

19.

Henry R, Strange P, Zhou R, Pettus J, Shi L, Zhuplatov S . Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Technol Ther. 2018; 20(11):715-724. PMC: 6208164. DOI: 10.1089/dia.2018.0052. View

20.

Gao F, Ma X, Peng J, Lu J, Lu W, Zhu W . The Effect of Acarbose on Glycemic Variability in Patients with Type 2 Diabetes Mellitus Using Premixed Insulin Compared to Metformin (AIM): An Open-Label Randomized Trial. Diabetes Technol Ther. 2019; 22(4):256-264. DOI: 10.1089/dia.2019.0290. View